This federal Project Grant award in the amount of $4,503,963 was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports a research project titled "Spatial Reprogramming of Tumor Immune Microenvironments by Preoperative Radiotherapy and Immune Checkpoint Inhibition in HER2 Negative Breast Cancer." The project is being led by the University of North Carolina at Chapel Hill (UNC-CH) through its Office of Sponsored Research, with a subaward to the Cleveland Clinic Foundation to oversee clinical data integration between the study's P-RAD and PEARL trials. The research aims to investigate innovative approaches using preoperative radiotherapy and immune checkpoint inhibition to reprogram tumor immune microenvironments in HER2-negative breast cancer. This work aligns with the program's focus on advancing medical solutions for military health needs and improving care for service members and veterans.